ESMO – European Society for Medical Oncology shared on LinkedIn:
“Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting adding to the current knowledge on how to integrate targeted and immunotherapy agents in the treatment planning.
Read the opinion by Marina Chiara Garassino in the ESMO Daily Reporter and learn what key questions remain unanswered.”
More posts featuring NSCLC.